848
V. V. Zarubaev et al. / Bioorg. Med. Chem. 18 (2010) 839–848
7. Hastings, J. C.; Selnick, H.; Wolanski, B.; Tomassini, J. E. Antimicrob. Agents
3.1.33. Cells and viruses
Chemother. 1996, 40, 1304.
For in vitro experiments MDCK cells (ATCC CCL 34) were used.
Experiments were performed with influenza virus A/Puerto Rico/
8/34 (H1N1) from the collection of viral strains from the Influenza
Research Institute. Virus was propagated in the allantoic cavity of
10–12 days old chicken embryos for 48 h at 36 °C.
8. Parkes, K. E.; Ermert, P.; Fassler, J.; Ives, J.; Martin, J. A.; Merrett, J. H.; Obrecht,
D.; Williams, G.; Klumpp, K. J. Med. Chem. 2003, 46, 1153.
9. Cianci, C.; Chung, T. D. Y.; Meanwell, N.; Putz, H.; Hagen, M.; Colonno, R. J.;
Krystal, M. Antiviral Chem. Chemother. 1996, 7, 353.
10. Furuta, Y.; Takahashi, K.; Fukuda, Y.; Kuno, M.; Kamiyama, T.; Kozaki, K.;
Nomura, N.; Egawa, H.; Minami, S.; Watanabe, Y.; Narita, H.; Shiraki, K.
Antimicrob. Agents Chemother. 2002, 46, 977.
11. Nakazawa, M.; Kadowaki, S.; Watanabe, I.; Kadowaki, Y.; Takei, M.; Fukuda, H.
Antiviral Res. 2008, 78, 194.
12. Plotch, S. J.; O’Hara, B.; Morin, J.; Palant, O.; LaRocque, J.; Bloom, J. D.; Lang, S.
A.; DiGrandi, M. J.; Bradley, M.; Nilakantan, R.; Gluzman, Y. J. Virol. 1999, 73,
140.
13. Luo, G.; Torri, A.; Harte, W. E.; Danetz, S.; Cianci, C.; Tiley, L.; Day, S.; Mullaney,
D.; Yu, K. L.; Ouellet, C.; Dextraze, P.; Meanwell, N.; Colonno, R.; Krystal, M. J.
Virol. 1997, 71, 4062.
14. Colacino, J. M.; DeLong, D. C.; Nelson, J. R.; Spitzer, W. A.; Tang, J.; Victor, F.;
Wu, C. Y. Antimicrob. Agents Chemother. 1990, 34, 2156.
15. Stamatiou, G.; Foscolos, G. B.; Fytas, G.; Kolocouris, A.; Kolocouris, N.; De
Clercq, E. Bioorg. Med. Chem. 2003, 11, 5485.
16. Lin, T.-I.; Heider, H.; Schroeder, C. J. Gen. Virol. 1997, 78, 767.
17. Kolocouris, A.; Kolocouris, N.; Foscolos, G. B.; De Clercq, E. J. Med. Chem. 1996,
39, 3310.
18. Zoidis, G.; Foscolos, G. B.; Fytas, G.; Padalko, E.; DeClercq, E.; Kolocouris, N.
Bioorg. Med. Chem. 2006, 14, 3341.
19. Zoidis, G.; Kolocouris, N.; Foscolos, G. B.; Kolocouris, A.; Fytas, G.; Padalko, E.;
DeClercq, E. Antiviral Chem. Chemother. 2003, 14, 153.
20. Kolocouris, A.; Foscolos, G. B.; Fytas, G.; Kolocouris, N.; DeClercq, E. Bioorg. Med.
Chem. Lett. 1999, 9, 3465.
3.1.34. Toxicity assay
For evaluation of anti-viral activity of compounds, MDCK cells
were seeded onto 96-wells plates and cultivated in Eagle’s minimal
essential medium (MEM) with addition of 5% fetal calf serum. After
the cell monolayer formed, cells were washed by serum-free MEM.
Azolo-adamantanes were dissolved in DMSO to 5 mg/ml, and serial
twofold dilutions (1000–1 microgram/ml) were prepared in MEM.
The dilutions were applied to the MDCK cells and incubated for
48 h at 37 °C. Cells were washed twice with PBS and the number
of survived cells were evaluated by a microtetrazolium test
(MTT).50 Briefly, 3-(4,5-dimethyltiazolyl-2) 2,5-diphenyltetrazoli-
um bromide (ICN Biochemicals Inc., Aurora, Ohio, 0,5 mg/ml,
0,1 ml per well) was added followed by incubation of plates at
37 °C in 5% CO2 for 60 min. Colored deposit was dissolved in 100
microliters of DMSO. The plates were swirled gently and left in
darkness at room temperature for 30 min. Optical density was
measured on a spectrophotometer (Victor 1420, Perkin Elmer, Fin-
land) at wavelength 535 nm. Based on these data, the CTD50 (com-
pound concentration required to reduce 50% cell viability) value
was estimated for each compound.
21. Stamatiou, G.; Kolocouris, A.; Kolocouris, N.; Fytas, G.; Foscolos, G. B.; De
Clercq, E. Bioorg. Med. Chem. Lett. 2001, 11, 2137.
22. Kolocouris, N.; Foscolos, G. B.; Kolocouris, A.; Fytas, G.; De Clercq, E. J. Med.
Chem. 1994, 37, 2896.
23. Stylinakis, I.; Kolocouris, N.; Kolocouris, A.; Fytas, G.; Foscolos, G. B.; Padalko,
E.; De Clercq, E. Bioorg. Med. Chem. Lett. 2000, 13, 1699.
24. Kolocouris, N.; Zoidis, G.; Foscolos, G. B.; Fytas, G.; Prathalingham, S. R.; Kelly, J.
M.; Naesens, L.; De Clercq, E. Bioorg. Med. Chem. Lett. 2007, 17, 4358.
25. Zoidis, G.; Tsotinis, A.; Kolocouris, N.; Kelly, J. M.; Prathalingham, S. R.;
Naesens, L.; De Clercq, E. Org. Biomol. Chem. 2008, 6, 3177.
26. Zoidis, G.; Kolocouris, N.; Naesens, L.; De Clercq, E. Bioorg. Med. Chem. 2009, 17,
1534.
27. Saraev, V. V.; Golod, E. L. Russ. J. Org. Chem. 1997, 33, 571.
28. Saraev, V. V.; Gavrilov, A. A.; Golod, E. L. Russ. J. Org. Chem. 1999, 35, 1069.
29. Saraev, V. V.; Kanakina, T. P.; Pevzner, M. S.; Golod, E. L.; Ugrak, B. I.; Kachala, V.
V. Russ. Chem. Heterocycl. Compd. 1996, 32, 928.
3.1.35. Antiviral assay
For evaluation of anti-viral activity of azolo-adamantanes, the
assay was performed by quantifying virus yield by the end-point
dilution method.51 Briefly, serial twofold dilutions of compounds
under investigation were prepared in MEM with addition of argi-
nine (2 mM), glutamine (2 mM) and trypsin (2 microgram/mL).
The solutions were applied to MDCK cells and incubated for 1 h
at 37 °C followed by infecting with influenza viruses in a dose 1–
106 50% infecting dose (ID50) in the medium. Control wells did
not contain the compounds. Viruses were cultivated at 36 °C for
48 h followed by hemagglutination assay. 100 microliters of super-
natant was transferred into round-bottom wells and mixed with
100 microliters of 1% chicken erythrocytes followed by 1 h incuba-
tion at room temperature. Virus titer was considered as reciprocal
to the final dilution of the inoculum able to cause positive hemag-
glutination in 50% of cells and expressed in 50% infecting doses.51
Anti-viral activity of the compounds were evaluated by their abil-
ity to decrease the virus titer. Based on the results, 50% effective
dose (concentration of compound that decreases the virus produc-
tion to 0.5 log10EID50) and the selectivity index (relation of CTD50
to ED50) were calculated.
30. Gavrilov, A. S.; Golod, E. L.; Kachala, V. V.; Ugrak, B. I. Russ. J. Org. Chem. 1999,
35, 1234.
31. Gavrilov, A. S.; Golod, E. L.; Kachala, V. V.; Ugrak, B. I. Russ. J. Org. Chem. 2001,
37, 1741.
32. Gavrilov, A. S.; Kachala, V. V.; Kuz’mina, N. E.; Golod, E. L. Russ. J. Gen. Chem.
2004, 74, 752.
33. Tsypin, V. G.; Kachala, V. V.; Ugrak, B. I.; Golod, E. L. Russ. J. Org. Chem. 2002, 38, 90.
34. Amandurdyeva, A. D.; Saraev, V. V.; Kuz’mina, N. E.; Golod, E. L. Russ. J. Gen.
Chem. 2004, 74, 1277.
35. Amandurdyeva, A. D.; Saraev, V. V.; Polyakova, I. N.; Golod, E. L. Russ. J. Gen.
Chem. 2005, 75, 130.
36. Amandurdyeva, A. D.; Saraev, V. V.; Polyakova, I. N.; Golod, E. L. Russ. J. Gen.
Chem. 2005, 75, 1475.
37. Gaponik, P. N.; Karavay, V. P.; Grigor’ev, Yu. V. Russ. Chem. Heterocycl. Compd.
1985, 21, 1422. Rus..
38. Chakrabarti, J. K.; Foulis, M. J.; Szinal, S. S. Tetrahedron Lett. 1968, 60, 6249.
39. Altland, H. W. J. Org. Chem. 1976, 41, 3395.
40. Logvinov, A. V.; Saraev, V. V.; Polyakova, I. N.; Strelenko, Yu. A.; Golod, E. L. Russ.
J. Gen. Chem. 2007, 77, 2186.
41. Kozeletskaia, K. N.; Grinbaum, E. B.; Zhamsrangiin, M.; Burmistrova, V. V.;
Kiselev, O. I. Vopr. Virusol. 1990, 35, 289.
References and notes
42. Hayden, F. G. Am. J. Med. 1997, 17, 55.
43. Stouffer, A. L.; Acharya, R.; Salom, D.; Levine, A. S.; Di Costanzo, L.; Soto, C. S.;
Tereshko, V.; Nanda, V.; Stayrook, S.; DeGrado, W. F. Nature 2008, 451, 596.
44. Schnell, J. R.; Chou, J. J. Nature 2008, 451, 591.
1. World Health Organization, Influenza: Report by the Secretariat. World Health
Assembly, WHO, Geneva, A56/23, 2004.
2. DeClercq, E. J. Clin. Virol. 2001, 22, 73.
45. White, L. K.; Yoon, J.-J.; Lee, J. K.; Sun, A.; Du, Y.; Fu, H.; Snyder, J. P.; Plemper, R.
K. Antimicrob. Agents Chemother. 2007, 51, 2293.
3. Scholtissek, C.; Quack, G.; Klenk, H. D.; Webster, R. G. Antiviral Res. 1998, 37, 83.
4. Lackenby, A.; Thompson, C. I.; Democratis, D. J. Curr. Opin. Infect. Dis. 2008, 21,
626.
5. Tomassini, J. E.; Davies, M. E.; Hastings, J. C.; Lingham, R.; Mojena, M.;
Raghoobar, S. L.; Singh, S. B.; Tkacz, J. S.; Goetz, M. A. Antimicrob. Agents
Chemother. 1996, 40, 1189.
6. Tomassini, J.; Selnick, H.; Davies, M. E.; Armstrong, M. E.; Baldwin, J.; Bourgeois,
M.; Hastings, J.; Hazuda, D.; Lewis, J.; McClements, W. Antimicrob. Agents
Chemother. 1994, 38, 2827.
46. Finnegon, W. G.; Henry, R. A.; Lofguist, R. J. Am. Chem. Soc. 1958, 80, 3908.
47. Lieber, E.; Ramachandran, J. Can. J. Chem. 1959, 37, 101.
48. Koreneva, A. P.; Koldobskii, G. I. Russ. J. Org. Chem. 1999, 35, 1511.
49. Gol’tsberg, M. A.; Koldobskii, G. I.; Tetrazoles Russ. J. Org. Chem. 1996, 32, 1194.
50. Mosmann, T. J. Immunol. Methods 1983, 65, 55.
51. Rimmelzwaan, G. F.; Baars, M.; Claas, E. C. J.; Osterhaus, A. D. M. E. J. Virol.
Methods 1998, 74, 57.